Murphy L J, Tachibana K, Friesen H G
Department of Physiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Endocrinology. 1988 May;122(5):2027-33. doi: 10.1210/endo-122-5-2027.
The effect of ovine PRL (oPRL) on hepatic insulin-like growth factor I (IGF-I) gene expression was examined in the hypophysectomized (hypox) rat and compared with that seen in hypox rats treated with ovine GH (oGH) and human GH (hGH). A single injection of oPRL (100 micrograms/100 g BW) resulted in a 15-fold increase in hepatic IGF-I messenger RNA abundance 12 h after administration. Serum IGF-I increased from 82.9 +/- (SE) 9.0 to 137.0 +/- 15.4 ng/ml. In acute studies, where the slopes of 4-point dose-response curves were compared, oPRL was approximately 50% as potent as oGH in stimulating serum IGF-I and hepatic IGF-I messenger RNA accumulation. In chronic experiments, where a single daily injection of oPRL (0, 10, 30, or 90 micrograms/day) was administered for 10 days, a significant increase in body wt was observed at each dose. However, in contrast to hypox rats which received oGH, no dose-response relationship was apparent, and oPRL was less than 10% as potent as oGH in this regard. A small but significant increase in serum IGF-I and hepatic IGF-I expression was observed in hypox rats chronically injected with oPRL when killed 6-7 h after the final injection. However, by extrapolation from the hGH dose-response curves, oPRL was 6.8% and 22.7% as potent as hGH in stimulating serum IGF-I and hepatic IGF-I accumulation respectively. The observations reported here demonstrate that oPRL has significant somatogenic activity in the rat as determined by the three variables measured. Whereas oPRL had significant effects on body weight gain, serum IGF-I and hepatic IGF-I expression, the potency of oPRL by comparison with the two other somatogenic hormones was more marked in acute experiments compared to the effects seen after chronic administration. These results suggest that oPRL, like human GH, has both somatogenic and lactogenic activity in the rat and therefore may be an inappropriate control in studies of the effects of somatogenic hormones in the rat.
研究了绵羊催乳素(oPRL)对垂体切除(hypox)大鼠肝脏胰岛素样生长因子I(IGF-I)基因表达的影响,并与用绵羊生长激素(oGH)和人生长激素(hGH)处理的hypox大鼠进行比较。单次注射oPRL(100微克/100克体重)导致给药后12小时肝脏IGF-I信使核糖核酸丰度增加15倍。血清IGF-I从82.9±(标准误)9.0纳克/毫升增至137.0±15.4纳克/毫升。在急性研究中,比较4点剂量反应曲线的斜率,oPRL在刺激血清IGF-I和肝脏IGF-I信使核糖核酸积累方面的效力约为oGH的50%。在慢性实验中,每天单次注射oPRL(0、10、30或90微克/天),持续10天,各剂量组体重均显著增加。然而,与接受oGH的hypox大鼠不同,未观察到剂量反应关系,在这方面oPRL的效力不到oGH的10%。在末次注射后6 - 7小时处死的长期注射oPRL的hypox大鼠中,观察到血清IGF-I和肝脏IGF-I表达有小幅但显著的增加。然而,根据hGH剂量反应曲线推断,oPRL在刺激血清IGF-I和肝脏IGF-I积累方面的效力分别为hGH的6.8%和22.7%。此处报告的观察结果表明,根据所测量的三个变量确定,oPRL在大鼠中具有显著的促生长活性。虽然oPRL对体重增加、血清IGF-I和肝脏IGF-I表达有显著影响,但与另外两种促生长激素相比,oPRL在急性实验中的效力比长期给药后的作用更明显。这些结果表明,oPRL与人生长激素一样,在大鼠中具有促生长和催乳活性,因此在大鼠促生长激素作用研究中可能不是合适的对照。